Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017.,JAMA Internal Medicine

当前位置： X-MOL 学术 › JAMA Intern. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017.
JAMA Internal Medicine ( IF 22.5 ) Pub Date : 2020-01-01 , DOI: 10.1001/jamainternmed.2019.3884
Andrew Sumarsono ₁ , Brendan M Everett ₂ , Darren K McGuire ₃ , Gregg C Fonarow ₄ , Javed Butler ₅ , Ambarish Pandey ₃ , Muthiah Vaduganathan ₂

Affiliation

There are now 12 classes of antihyperglycemic medications available for patients with type 2 diabetes mellitus (DM). With an estimated 30 million patients in the United States living with DM¹ and increasing complexity and financial burden of DM care, the relative distribution of expenditures across DM therapeutic classes needs to be reexamined. We evaluated trends in aggregate use and expenditures for all DM therapies among US Medicare Part D beneficiaries from 2012 to 2017.

中文翻译：

2012 年至 2017 年美国医疗保险受益人抗高血糖治疗的总体使用和相关支出趋势。

现在有 12 类抗高血糖药物可用于 2 型糖尿病 (DM) 患者。在美国，估计有 3000 万 DM ¹患者，并且 DM 护理的复杂性和经济负担不断增加，因此需要重新检查 DM 治疗类别之间的支出相对分布。我们评估了 2012 年至 2017 年美国医疗保险 D 部分受益人所有 DM 疗法的总体使用和支出趋势。

更新日期：2020-01-06

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11